N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

• Status: RECRUITING
• Trial end date: 2029-07-22

Summary

The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

• Phase: PHASE2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Treatments: Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; etoposide phosphate; Granulocyte-Macrophage Colony-Stimulating Factor; Ifosfamide; Irinotecan; naxitamab; sargramostim; Temozolomide; Topotecan; Vincristine